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*n.b. The errors and associated corrections described in this document concerning the original manuscript were accountable to the production department handling this manuscript, and thus are no fault of the authors of this paper.*

In the original publication of this article \[[@CR1]\], the tables were inadvertently omitted. These can be found below:Table 1Demographic and baseline clinical characteristics of patients with spontaneous bacterial peritonitisVariable*Enterobacter* SBP\
(*n =* 32)*E. coli* SBP\
(*n =* 128)*P*Male sex26 (81.3)104 (81.3)Age, years (mean ± SD)55 ± 10.955 ± 11.7SBP subtype0.03 Definite SBP^a^26 (81.2)78 (60.9) Probable SBP^b^6 (18.8)50 (39.1)Place of acquisition\<0.001 Community12 (37.5)98 (76.6) Hospital20 (62.5)30 (23.4)Concomitant hepatocellular carcinoma21 (65.6)48 (37.5)0.004Causes of liver cirrhosis0.79 Hepatitis B virus21 (65.6)88 (68.8) Hepatitis C virus2 (6.2)13 (10.2) Alcoholism6 (18.8)19 (14.8) Others3 (9.4)8 (6.2)Child-Pugh class0.006 A1 (3.1)0 (0) B10 (31.3)17 (13.3) C21 (65.6)111 (86.7)MELD score, median (IQR)19 (15--24)23 (18--29)0.03Underlying diseases Diabetes mellitus9 (28.1)25 (19.5)0.29 Alcoholism6 (18.8)23 (18.0)0.92 Solid cancer (other than hepatoma)3 (9.4)4 (3.1)0.14 Chronic kidney disease1 (3.1)2 (1.6)0.49 Solid organ transplantation1 (3.1)0 (0)0.20Comorbid conditions Transarterial chemoembolization (\<30 days)4 (12.5)4 (3.1)0.052 Endoscopic intervention (≤30 days)8 (25.0)7 (5.5)0.001 Varix control56 ERCP31Systemic anticancer chemotherapy (≤30 days)3 (9.4)0 (0)0.007Prior hospitalization (≤90 days)26 (81.2)74 (57.8)0.01Prior antimicrobial therapy (\<30 days)19 (59.4)36 (28.1)0.001Values are n (%) unless otherwise indicated. *MELD* model for end-stage liver disease, *IQR* interquartile range*ERCP* endoscopic retrograde cholangiopancreatography^a^Ascites culture was positive^b^Ascites culture was negative, while blood culture was positive without any other primary focusTable 2Clinical manifestations and laboratory findings of patients with spontaneous bacterial peritonitis by study groupVariable*Enterobacter* SBP\
(*n =* 32)*E. coli* SBP\
(*n =* 128)*P*Initial clinical manifestation, n (%) Abdominal pain23 (71.9)90 (70.3)0.86 Fever24 (75.0)87 (68.0)0.44 Hepatic encephalopathy6 (18.8)34 (26.6)0.36 Septic shock5 (15.6)31 (24.2)0.30Upper gastrointestinal bleeding, n (%)9 (28.1)12 (9.4)0.005 Variceal bleeding711 Ulcer bleeding11 Duodenal invasion of cancer10Concomitant bacteremia, n (%)11 (34.4)87 (68.0)0.001Laboratory finding, median (IQR) Serum WBC, cells/μL8,050 (5,125 − 13,200)6,450 (4,400 − 9,675)0.12 Platelets, x 10/mL61 (44--104)62 (41--85)0.15 C-reactive protein, mg/dL6.41 (2.1--7.9)3.06 (1.1--6.2)0.06 Serum creatinine, mg/dL1.2 (0.9--1.5)1.2 (0.9--1.7)0.80 Serum bilirubin, mg/dL3.8 (2.6--12.2)5.3 (3.5--10.3)0.79 Ascites WBC, cells/μL6,160 (1,945--11,795)5,360 (2,690--11,960)0.45 Ascites neutrophils, cells/μL5,058 (1,483--10,899)4,275 (2,092--10,771)0.46Ascites protein, mg/dL1.5 (1.0--2.5)1.0 (0.8--1.4)0.003*WBC* white blood cells, *IQR* interquartile rangeTable 3Antimicrobial susceptibility of isolates of *Enterobacter* species and *Escherichia coli*Antimicrobial^a^*Enterobacter* SBP\
(*n =* 31)*E. coli* SBP\
(*n =* 125)*P*Cefotaxime23/31 (74.2)106/125 (84.8)0.16Ceftazidime22/31 (71.0)106/125 (84.8)0.07Ceftriaxone22/31 (71.0)106/125 (84.8)0.07Third-generation cephalosporins^b^22/31 (71.0)106/125 (84.8)0.07Cefepime25/29 (86.2)103/123 (83.7)1.00Ciprofloxacin25/31 (80.6)76/125 (60.8)0.038Piperacillin/tazobactam23/31 (74.2)116/125 (92.8)0.003Imipenem31/31 (100.0)125/125 (100.0)1.00Trimethoprim-sulfamethoxazole27/31 (87.1)74/125 (59.2)0.003Amikacin30/31 (96.8)124/125 (99.2)0.36Gentamicin27/31 (87.1)84/125 (67.2)0.03Tobramycin27/31 (87.1)81/125 (64.8)0.02Values are n (%) unless otherwise indicated^a^Not all of the isolates underwent susceptibility testing^b^Means cefotaxime or ceftriaxone. The susceptibility to third-generation cephalosporins was defined by the breakpoints of the 2008 Clinical Laboratory Standards Institute guidelines (susceptible, ≤ 8 μg/ml; intermediate, 16--32 μg/ml; and resistant, ≥ 64 μg/ml) \[18\]Table 4Treatments and outcomes in patients with spontaneous bacterial peritonitis caused by *Enterobacter* species and *Escherichia coli*Variable*Enterobacter* SBP (*n =* 32)*E. coli* SBP (*n =* 128)*P*Initial empirical antimicrobial agent Cefotaxime27 (84.4)116 (90.6)0.31 Imipenem or meropenem4 (12.4)9 (7.0) Cefazolin1 (3.1)0 (0) Ceftazidime0 (0)1 (0.8) Cefepime0 (0)1 (0.8) Levofloxacin0 (0)1 (0.8)Appropriateness of initial therapy27 (87.1)109 (87.2)1.00Initial response to empirical treatment^a^26/32 (81.3)95/117 (81.2)0.995Emergence of resistance during third-generation cephalosporin treatment1/23 (4.3)0/98 (0)0.19Duration of hospitalization, median days (IQR) Overall20 (11--31)16 (10--26)0.28 Survivors22 (12--31)16 (11--26)0.41Duration of antimicrobial use, median days (IQR) Overall15 (11--25)13 (8--16)0.02 Survivors16 (13--29)13 (10--16)0.01ICU care during admission2 (6.2)19 (14.8)0.25Mortality 14-day mortality7 (21.9)25 (19.5)0.77 30-day mortality12 (37.5)37 (28.9)0.35 In-hospital mortality12 (37.5)28 (21.9)0.07Values are n (%) unless otherwise indicated. *IQR* interquartile range, *ICU* intensive care unit^a^Ascitic neutrophil decrease \>25 % observed 48--72 h after initiating antimicrobials

The online version of the original article can be found under doi:10.1186/s12879-016-1595-y.
